This was posted on IHUB by another poster: "Brilacidin the endless headed monster" -
I remember part of the interview from former CEO of Poly " That’s absolutely right. That is one of the very significant medical needs and commercial opportunities is for IV tubes and catheters. That was one of the other reasons we picked the antibiotic area to work in as our first product development program. In addition to developing the antibiotic drugs which we believe bacterial resistance is unlikely to develop, there are also polymer derivatives of these. So, our idea is to have more shots on goal. To have more ways of applying our same basic invention of the synthetic chemicals we’ve created to imitate these host defense proteins. With the polymers, the biomaterials applications, what we’ve done is we’ve shown that we can take polymer forms of these drugs and we can add them to paint, plastic and textiles to make materials and surfaces self sterilizing an antimicrobial. There are many, many potential applications of that. So, if we look at the world around us and think, where would it be good to have a surface that would be self sterilizing, that would kill bacteria on contact? It’s many places. There are many medical applications. As we’ve mentioned, catheters and IV tubes, bandages, surgical gloves and masks, many industrial applications, like coating the interiors of hospitals, restaurants, schools, many consumer products, such as soaps, lotions, cosmetics, contact lenses and contact lens cleaning solutions. The idea is to take these polymers and add them to these types of plastics and coating. So then that could make the material itself self sterilizing an antimicrobial.
My response on IHUB: Top123's post 214697 shows why everyone has been way, way too conservative on the value of the B platform. It's uses are so widespread that no current valuation is possible.
To have a product that can be incorporated into textiles, paints, plastics, etc, etc means that B will have an ungodly amount of universal applications not involving patients per se.
Instead of a product that is ingested or aimed at specific patients, it will be incorporated into a plethora of products across a wide spectrum of everyday life for everyone on the planet making all of these products antimicrobial and self-sterilizing.
Many are reluctant to give a value of the B platform because they will be ridiculed by those with agendas against the company, but IMO B could become one of the largest industrial components in the world in addition to being one of the largest drugs in the world of medicine.
I also believe we will find Kevetrin following a path the likes of B in that it is going to be found to be so compatible with so many other medical products that it will startle everyone.
I remember part of the interview from former CEO of Poly " That’s absolutely right. That is one of the very significant medical needs and commercial opportunities is for IV tubes and catheters. That was one of the other reasons we picked the antibiotic area to work in as our first product development program. In addition to developing the antibiotic drugs which we believe bacterial resistance is unlikely to develop, there are also polymer derivatives of these. So, our idea is to have more shots on goal. To have more ways of applying our same basic invention of the synthetic chemicals we’ve created to imitate these host defense proteins. With the polymers, the biomaterials applications, what we’ve done is we’ve shown that we can take polymer forms of these drugs and we can add them to paint, plastic and textiles to make materials and surfaces self sterilizing an antimicrobial. There are many, many potential applications of that. So, if we look at the world around us and think, where would it be good to have a surface that would be self sterilizing, that would kill bacteria on contact? It’s many places. There are many medical applications. As we’ve mentioned, catheters and IV tubes, bandages, surgical gloves and masks, many industrial applications, like coating the interiors of hospitals, restaurants, schools, many consumer products, such as soaps, lotions, cosmetics, contact lenses and contact lens cleaning solutions. The idea is to take these polymers and add them to these types of plastics and coating. So then that could make the material itself self sterilizing an antimicrobial.
My response on IHUB: Top123's post 214697 shows why everyone has been way, way too conservative on the value of the B platform. It's uses are so widespread that no current valuation is possible.
To have a product that can be incorporated into textiles, paints, plastics, etc, etc means that B will have an ungodly amount of universal applications not involving patients per se.
Instead of a product that is ingested or aimed at specific patients, it will be incorporated into a plethora of products across a wide spectrum of everyday life for everyone on the planet making all of these products antimicrobial and self-sterilizing.
Many are reluctant to give a value of the B platform because they will be ridiculed by those with agendas against the company, but IMO B could become one of the largest industrial components in the world in addition to being one of the largest drugs in the world of medicine.
I also believe we will find Kevetrin following a path the likes of B in that it is going to be found to be so compatible with so many other medical products that it will startle everyone.
10
